Expert panel

continued from page 9

There has been a recent emergence of several new agents and treatment approaches for men with advanced prostate cancer in a variety of settings, Dr Singa said. The challenge for clinicians, however, is deciding on the optimal strategy at the individual patient level.

“As a clinician, I found the paper useful as the survey questions represent scenarios that patients and physicians face every day,” said Saum Ghodoussipour, MD, a urologic oncologist who is an assistant professor of surgery at Rutgers Robert Wood Johnson Medical School and Director of the Bladder and Urothelial Cancer Program at Rutgers Cancer Institute of New Jersey in New Brunswick. “The varied consensus reflects limitations in the existing literature and most importantly, the new gaps in understanding that we are fortunate to face with the development of advanced imaging modalities and novel androgen receptor pathway inhibitors and antaghonists.”

While the findings of this panel do not fill any knowledge gaps or provide “guideline level” evidence, they suggest that most of the questions raised can be better addressed through PSMA PET, novel drugs, genomic classifiers, and patient reported outcomes in ongoing trials. Dr Ghodoussipour said the needle is likely to continue to move in PCa care and new questions will arise. “Expert consensus statements like this will always be welcomed so that we can push to provide the best treatments and outcomes for our patients,” Dr Ghodoussipour said. ■